Abstract
The heterogeneity of neuroblastic tumors added to the immense biological complexity has led to an unprecedented scale of investigations and a growing list of molecular genetic targets for prognosis as well as therapy. Recently, Anaplastic Lymphoma Kinase (ALK) has been identified as a major predisposing gene as well as a potential therapeutic target for neuroblastoma. Individuals with ALK-related neuroblastoma susceptibility (i.e., heterozygous for an ALK mutation) are at risk of developing neuroblastic tumors. Aberrant copy number or mutations in ALK gene and overexpression of its protein tyrosine-kinase receptor have been related to poor prognosis of this disease, although a great degree of discrepancy exists regarding the clinical validation of these alterations. Molecular diagnostic laboratories currently evaluate only the tyrosine kinase domain (exons 21-28) of the ALK gene. To date, all reported disease-associated ALK mutations are located in the tyrosine kinase domain and the majority are thought to be drivers of an oncogenic process. However, these mutational studies are robust and are not feasible in the clinical setting especially on clinical samples of neuroblastoma. In addition, an effective clinical assay has not yet been validated for assessing whether the genetic status of ALK provides useful prognostic information for planning treatment strategy for neuroblastoma patients. A simple and cost-effective approach to implement in clinical practice would be to develop a test that can determine the DNA copy number alterations of ALK gene in clinical samples of neuroblastoma. Interphase fluorescence in situ hybridization (FISH) analysis of ALK gene with tissue microarrays would be an ideal example to suit the above mentioned objective. This review summarizes the role of FISH as a molecular genetic test in detecting copy number alterations of ALK gene in formalin-fixed paraffin embedded (FFPE) samples using our data on series of sporadic primary neuroblastomas.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471–1482
Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O’Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21:2077–2084
Berthier A, Piqueras M, Villamon E, Berbegall A, Tadeo I, Castel V, Navarro S, Noguera R (2011) ALK expression in neuroblastomas and its relationship with genetic, prognostic and predictive factors. Hum Pathol 42:301–302
Bown N, Cotterill S, Lastowska M, O’Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954–1961
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477
Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40:2256–2263
Capasso M, Diskin SJ (2010) Genetics and genomics of neuroblastoma. Cancer Treat Res 155:65–84
Caren H, Abel F, Kogner P, Martinsson T (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416:153–159
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, Nakagawara A, Hayashi Y, Mano H, Ogawa S (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971–974
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16:4353–4362
George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975–978
Iwasaki H, Nabeshima K, Nishio J, Jimi S, Aoki M, Koga K, Hamasaki M, Hayashi H, Mogi A (2009) Pathology of soft-tissue tumors: daily diagnosis, molecular cytogenetics and experimental approach. Pathol Int 59:501–521
Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967–970
Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M (2007) Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. J Cancer Res Clin Oncol 133:185–192
Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY (2010) Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int 60:510–515
Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, Mariame B (2000) Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156:1711–1721
Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone A (2002) Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 62:301–306
Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS (2007) Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26:7432–7444
Machado I, Noguera R, Pellin A, Lopez-Guerrero JA, Piqueras M, Navarro S, Llombart-Bosch A (2009) Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR. Diagn Mol Pathol 18:189–199
McArdle L, McDermott M, Purcell R, Grehan D, O’Meara A, Breatnach F, Catchpoole D, Culhane AC, Jeffery I, Gallagher WM, Stallings RL (2004) Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis 25:1599–1609
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284
Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930–935
Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C, Racaud-Sultan C, Gonzalez-Dunia D, Vigny M, Mehlen P, Delsol G, Allouche M (2006) Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26:6209–6222
Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847–854
Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759–767
Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R (2005) Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167:213–222
Palmer RH, Vernersson E, Grabbe C, Hallberg B (2009) Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420:345–361
Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda M, Gregorio A, Gambini C, Garaventa A, Pistoia V, Del Grosso F, Tonini GP, Cheng M, Gambacorti-Passerini C, Anichini A, Fossati-Bellani F, Di Nicola M, Luksch R (2009) Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69:7338–7346
Piqueras M, Navarro S, Castel V, Canete A, Llombart-Bosch A, Noguera R (2009) Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatr Blood Cancer 52:209–214
Piqueras M, Navarro S, Canete A, Castel V, Noguera R (2011) Prognostic value of partial genetic instability in Neuroblastoma with ≤50% neuroblastic cell content. Histopathology 59:22–30
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372
Spieker N, Beitsma M, van Sluis P, Roobeek I, den Dunnen JT, Speleman F, Caron H, Versteeg R (2000) An integrated 5-Mb physical, genetic, and radiation hybrid map of a 1p36.1 region implicated in neuroblastoma pathogenesis. Genes Chromosomes Cancer 27:143–152
Spitz R, Hero B, Simon T, Berthold F (2006) Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 12:3368–3373
Squire JA, Thorner PS, Weitzman S, Maggi JD, Dirks P, Doyle J, Hale M, Godbout R (1995) Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 10:1417–1422
Stock C, Bozsaky E, Watzinger F, Poetschger U, Orel L, Lion T, Kowalska A, Ambros PF (2008) Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. Am J Pathol 172:203–214
Subramaniam MM, Noguera R, Piqueras M, Navarro S, Lopez-Guerrero JA, Llombart-Bosch A (2006) p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. Am J Clin Pathol 126:866–874
Subramaniam MM, Noguera R, Piqueras M, Navarro S, Carda C, Pellin A, Lopez-Guerrero JA, Llombart-Bosch A (2007) Evaluation of genetic stability of the SYT gene rearrangement by break-apart FISH in primary and xenotransplanted synovial sarcomas. Cancer Genet Cytogenet 172:23–28
Subramaniam MM, Piqueras M, Navarro S, Noguera R (2009) Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol 40:1638–1642
Sugimura H, Mori H, Nagura K, Kiyose S, Hong T, Isozaki M, Igarashi H, Shinmura K, Hasegawa A, Kitayama Y, Tanioka F (2010) Fluorescence in situ hybridization analysis with a tissue microarray: ‘FISH and chips’ analysis of pathology archives. Pathol Int 60:543–550
Acknowledgment
This study was supported by grants: RD06/0020/0102 from RTICC, ISCIII & ERDF and 396/2009 from FAECC.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Piqueras, M., Subramaniam, M.M., Berthier, A., Navarro, S., Noguera, R. (2012). A Comprehensive Tissue Microarray-Based FISH Screen of ALK Gene in Neuroblastomas. In: Hayat, M. (eds) Neuroblastoma. Pediatric Cancer, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2418-1_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-2418-1_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2417-4
Online ISBN: 978-94-007-2418-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)